PRINCETON, N.J., Sept. 19 /PRNewswire-FirstCall/ -- Cytogen Corporation (Nasdaq: CYTO - News) today announced the publication of new data relating to the Company’s QUADRAMET® (samarium Sm-153 lexidronam injection) product. The publication, “Incident pain and analgesic consumption decrease after samarium infusion: a pilot study” appears in a recent issue of the peer-reviewed journal Supportive Care in Cancer (Support Care Cancer. 2006 Sep 12).
